ALAR PHARMACEUTICALS INC.

Highlights Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-02 EDT			5-day change	1st Jan Change
276 ^TWD	-3.16%		-5.80%	+31.74%

05-10	Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-14	Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan	03-07	CI
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023, Payable on June 28, 2024	03-06	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office	02-22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office	02-22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial	02-19	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals	23-10-11	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-03	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000	22-01-12	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-13	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
Alar Presents Positive Interim Results of Long-Acting Buprenorphine Injectable in Opioid Dependent Patients	21-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer